Observational study / 2012
Pre-diagnostic biomarkers of acrylamide exposure were linked to higher breast cancer-specific mortality among non-smoking postmenopausal Danish women.
Researchers evaluated whether pre-diagnostic acrylamide exposure, measured via acrylamide and glycidamide hemoglobin adducts (AA-Hb and GA-Hb), was associated with mortality in 420 postmenopausal women who developed breast cancer. Blood samples were analyzed using Cox proportional hazard models. Among non-smokers, higher GA-Hb levels per 25 pmol/g globin were associated with higher breast cancer-specific mortality (HR: 1.63, 95% CI: 1.06-2.51), reaching an HR of 2.23 (95% CI: 1.38-3.61) among those with estrogen receptor-positive tumors. For AA-Hb, higher levels were statistically significantly associated with mortality among women with estrogen receptor-positive tumors (HR: 1.31, 95% CI: 1.02-1.69).
Shows an association, not proof of cause and effect.
- Study type
- Prospective cohort study
- Who was studied
- 420 postmenopausal Danish women with breast cancer (from a cohort of 24,697)
- What was measured
- Mortality after breast cancer diagnosis
THE PAPER
Pre-diagnostic acrylamide exposure and survival after breast cancer among postmenopausal Danish women.
Olsen A, Christensen J, Outzen M, Olesen PT, Frandsen H, Overvad K, Halkjær J. Toxicology, 2012.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.